Poor-Prognosis Metastatic NSGCT: What to Do When BEP Produces an Unfavourable Tumour Marker Decline

Clinical scenario

This protocol targets patients with non-seminomatous germ cell tumour (NSGCT) and metastatic disease in the IGCCCG poor prognosis group who fail to achieve a favourable serum tumour marker decline after the first cycle of first-line chemotherapy.

IGCCCG poor prognosis — defining criteria

Poor prognosis is established by any one of the following:

Mediastinal primary tumour
Non-pulmonary visceral metastases
AFP > 10,000 ng/mL
hCG > 50,000 IU/L
LDH > 10 × upper limit of normal

First-line failure — why this protocol is reached

First-line treatment (BEP, or VIP when bleomycin is contraindicated) is expected to produce a favourable serum tumour marker decline after cycle 1 and eventual normalization of AFP, hCG, and LDH. When the decline after the first chemotherapy cycle is classified as unfavourable, the standard first-line course alone is insufficient and escalation of treatment intensity is indicated.

Treatment approach (partial)

When an unfavourable marker decline is identified early, a dose-dense (intensified) chemotherapy regimen — delivered at a higher dose frequency than the standard schedule — replaces the remaining cycles of the initial regimen. The complete protocol, including agent selection, sequencing, and supportive-care requirements, is available via the structured evidence-based summary below.

Full regimen details are in the structured protocol.

Treatment goals

Normalization of serum tumour markers (AFP, hCG, LDH) and radiological response on cross-sectional imaging.

Instant Access to Structured Evidence-Based Regimens

References

Any of the following criteria: Mediastinal primary, Non-pulmonary visceral metastases, AFP > 10,000 ng/mL, hCG > 50,000 IU/L (10,000 ng/mL), LDH > 10 x ULN.
Treat metastatic NSGCT with a poor prognosis and favourable marker decline with four cycles of BEP.
An RCT demonstrated improved PFS when intensifying treatment with dose-dense chemotherapy in patients with an early unfavourable tumour marker decline.
Patients with an unfavourable tumour marker decline after BEP x 1 can be switched to a more intensive (dose-dense) chemotherapy regimen.
With unfavourable decline, consider chemotherapy intensification.

View source ↗